74156-75-5

Upstream product

• 138505-14-3 2-(3,4-dimethoxyphenyl)propanoic acid 
• 18066-68-7 ethyl 3,4-dimethoxyphenylacetate 
• 93-40-3 (3,4-Dimethoxyphenyl)acetic acid 

Downstream Products

• 74156-76-6 <1-(3,4-Dimethoxyphenyl)-ethyl>-(4-phenylpiperidino)-keton 
• 55174-61-3 2-(3,4-dimethoxyphenyl)propan-1-amine 
• 110117-95-8 (-)-N-((S)-α-methylbenzyl)-2(R)-(3,4-dimethoxyphenyl)propylamine 
• 110117-98-1 N-((R)-α-methylbenzyl)-2(R)-(3,4-dimethoxyphenyl)propylamine 
• 110117-96-9 N-((S)-α-methylbenzyl)-2(S)-(3,4-dimethoxyphenyl)propylamine 
• 110117-97-0 N-((R)-α-methylbenzyl)-2(S)-(3,4-dimethoxyphenyl)propylamine 
• 110117-90-3 N-benzyl-2-(3,4-dimethoxyphenyl)propylamine 
• 64265-63-0 (S)-2-(3,4-dimethoxyphenyl)-propan-1-amine 
• 213616-73-0 (S)-2-(3,4-dihydroxyphenyl)propylamine 
• 752152-76-4 N-<2-(3,4-Dimethoxyphenyl)-propyl>-4-phenylpiperidine 
• 74156-78-8 4-<1-(4-Phenylpiperidinomethyl)-ethyl>-benzol-1,2-diol-hydrobromid 
• 110117-91-4 N-((R)-α-methylbenzyl)-2(RS)-(3,4-dimethoxyphenyl)propanamide 
• 110117-91-4 N-((S)-α-methylbenzyl)-2(RS)-(3,4-dimethoxyphenyl)propanamide 

Relevant academic research and scientific papers

Novel dihydroquinolizinones for the treatment and prophylaxis of hepatitis B virus infection

The invention provides novel compounds having the general formula: wherein R1, R2, R3, R4, R5 and R6 are as described herein, compositions including the compounds and methods of using the compounds.

NOVEL DIHYDROQUINOLIZINONES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION

The invention provides novel compounds having the general formula (I) wherein R1, R2 R3, R4, R5 and R6 are as described herein, compositions including the compounds and methods of using the compounds in the treatment of the hepatitis B virus.

2, 6 BISHETEROARYL-4-AMINOPYRIMIDINES AS ADENOSINE RECEPTOR ANTAGONISTS

4-Aminopyrimidine derivatives of formula (I) FORMULA heteroaryl groups, including pharmaceutically acceptable salts thereof, wherein R1 and R2 are adenosine A2A receptor antagonists useful in the treatment of movement disorders such as Parkinson's disease.

Effect of β-Alkyl Substitution on D-1 Dopamine Agonist Activity: Absolute Configuration of β-Methyldopamine

β-Methyldopamine and its enantiomers and racemic β-phenyldopamine were synthesized and evaluated for dopamine D-1 agonist activity.In the dopamine-sensitive adenylate cyclase assay, β-phenyldopamine had about one-sixth the activity of dopamine.Racemic β-m